Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness: A Retrospective Multi-institutional Cohort Analysis
Overview
- Phase
- Not Applicable
- Intervention
- Immunotherapy
- Conditions
- Lung Cancer
- Sponsor
- Sun Yat-sen University
- Enrollment
- 209
- Locations
- 1
- Primary Endpoint
- Complete pathologic response
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness.
Investigators
Hao Long
Professor
Sun Yat-sen University
Eligibility Criteria
Inclusion Criteria
- •pathologically-confirmed diagnosis of NSCLC by pretreatment biopsy
- •clinically staged as T1-4N0-2M0
- •having undergo neoadjuvant chemoimmunotherapy
- •the agents of immune checkpoint inhibitors (ICIs) belong to PD-1/L1 inhibitors
- •having undergo surgery with lymph nodes (LNs) dissection
- •having postoperative pathology reports with evaluation of primary tumor and LNs response
- •having accessible pretreatment and preoperative radiology examinations imaging or reports
Exclusion Criteria
- •using PD-1/L1 inhibitors in the phase of clinical trials
- •the agents of neoadjuvant therapy including angiogenesis inhibitors
- •having undergone radiotherapy to treat primary tumor or metastatic LNs before surgery
Arms & Interventions
Neoadjuvant immunochemotherapy NSCLC group
NSCLC patients who received neoadjuvant immunochemotherapy and underwent surgery.
Intervention: Immunotherapy
Outcomes
Primary Outcomes
Complete pathologic response
Time Frame: through study completion, an average of 3 months
Tumors with 0% viable tumor cells
Secondary Outcomes
- Major pathologic response(through study completion, an average of 3 months)
- Complete pathologic response in lymph nodes(through study completion, an average of 3 months)